Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Biotech
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Evorpacept failed to meet the primary endpoints of two head and neck cancer trials, causing the company to scrap further attempts in the indication.
Darren Incorvaia
Apr 25, 2025 2:25pm
'One of the lucky few': Bicara CEO on last year's $326M IPO
Apr 14, 2025 3:59pm
Avacta hits 10% response rate, adds peptide-drug conjugate arms
Jan 16, 2025 8:51am
Merus touts cancer drug's strong profile with new data drop
Dec 2, 2024 11:59am
Pyxis' shares fall on lukewarm early ADC results in solid tumors
Nov 21, 2024 2:30pm
Ultimovacs cancer vaccine fails again, enters last chance saloon
Aug 6, 2024 4:14am
